Disease modifying therapy for AD?

Journal of Neurochemistry

Volumn 99, Issue 3, 2006, Pages 689-707

  Golde, Todd E ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; AF 267B; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; AR A014418; BETA SECRETASE INHIBITOR; CAD 106; CHAPERONE; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN CONVERTING ENZYME; EPIGALLOCATECHIN GALLATE; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; INOSITOL DERIVATIVE; LEVO FLURBIPROFEN; MEMANTINE; MEMBRANE METALLOENDOPEPTIDASE; MUSCARINIC M1 RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENSERINE; PLASMIN; SCYLLO INOSITOL; SRN 003 556; STATINE DERIVATIVE; SULFONIC ACID DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COST OF ILLNESS; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ECONOMIC ASPECT; ENZYME ACTIVITY; HUMAN; MENINGOENCEPHALITIC LIKE SYMPTOM; MENINGOENCEPHALITIS; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; IMMUNOTHERAPY; MOLECULAR CHAPERONES; NEUROFIBRILLARY TANGLES; PEPTIDE HYDROLASES; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN FOLDING; TAU PROTEINS;

ANIMALIA;

EID: 33750082029     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04211.x     Document Type: Review

References (247)

1. Abad-Rodriguez J., Ledesma M. D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B. and Dotti C. G. (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 167, 953-960.
2. Abraham C. R. and Potter H. (1989) Alpha 1-antichymotrypsin in brain aging and disease. Prog. Clin. Biol. Res. 317, 1037-1048.
3. Adlard P. A., Perreau V. M., Pop V. and Cotman C. W. (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 4217-4221.
4. Agadjanyan M. G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T. and Cribbs D. H. (2005) Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 1580-1586.
5. Aisen P. S., Schafer K. A., Grundman M., Pfeiffer E., Sano M., Davis K. L., Farlow M. R., Jin S., Thomas R. G. and Thal L. J. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama 289, 2819-2826.
6. Akiyama H., Barger S., Barnum S. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
7. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K. L., Barde Y. A., Duff K. and Davies P. (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590.
8. Aniello F., Couchie D., Bridoux A. M., Gripois D. and Nunez J. (1991) Splicing of juvenile and adult tau mRNA variants is regulated by thyroid hormone. Proc. Natl Acad. Sci. U S A 88, 4035-4039.
9. Arbel M., Yacoby I. and Solomon B. (2005) Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc. Natl Acad. Sci. U S A 102, 7718-7723.
10. Bard F., Barbour R., Cannon C. et al. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. U S A 100, 2023-2028.
11. Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
12. Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E. and Holtzman D. M. (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856-861.
13. Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I. and Shearman M. S. (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site-evidence for an allosteric mechanism. J. Biol. Chem. 279, 43 419-43 426.
14. von Bergen M., Barghorn S., Li L., Marx A., Biernat J., Mandelkow E. M. and Mandelkow E. (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J. Biol. Chem. 276, 48 165-48 174.
15. Black S., Wilcock G. K., Hawworth J., Hendrix S., Zavitz K., Christensen D. b. M.-H., Bass S., Laughlin M. and Swabb E. (2006) Efficacy and safety ofMPC-7869 (R.-flurbiprofen), a selective Abeta42 loering agent in mild Alzheimer's disease: results of a 12-month phase 2 trial and 1-year follow on study. Neurology 66, A347.
16. Blennow K. (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. Neurorx. 1, 213-225.
17. Bodovitz S. and Klein W. L. (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436-4440.
18. Buxbaum J. D., Liu K. N., Luo Y., Slack J. L., Stocking K. L., Peschon J. J., Johnson R. S., Castner B. J., Cerretti D. P. and Black R. A. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 27 765-27 767.
19. Caccamo A., Oddo S., Billings L. M., Green K. N., Martinez-Coria H., Fisher A. and LaFerla F. M. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671-682.
20. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233-234.
21. Calon F., Lim G. P., Yang F. et al. (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645.
22. Chackerian B., Rangel M., Hunter Z. and Peabody D. S. (2006) Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 24, 6321-6331.
23. Cherny R. A., Atwood C. S., Xilinas M. E. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
24. Choi D. S., Wang D. Yu G. Q. Zhu G. Kharazia V. N. Paredes J. P. Chang W. S. Deitchman J. K. Mucke L. and Messing R. O. (2006) PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc. Natl Acad. Sci. U S A 103, 8215-8220.
25. Cirrito J. R. Deane R. Fagan A. M. et al. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest 115, 3285-3290.
26. Cotman C. W., Poon W. W., Rissman R. A. and Blurton-Jones M. (2005) The role of caspase cleavage of tau in Alzheimer disease neuropathology. J. Neuropathol. Exp. Neurol. 64, 104-112.
27. Craft S. (2005) Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 26, 65-69.
28. Cuadrado A., Garcia-Fernandez L. F., Imai T., Okano H. and Munoz A. (2002) Regulation of tau RNA maturation by thyroid hormone is mediated by the neural RNA-binding protein musashi-1. Mol. Cell Neurosci. 20, 198-210.
29. Curtain C. C., Ali F., Volitakis I., Cherny R. A., Norton R. S., Beyreuther K., Barrow C. J., Masters C. L., Bush A. I. and Barnham K. J. (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276, 20 466-20 473.
30. Das P., Golde T. E. (2002) Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al. Neurobiol. Aging 23, 671.
31. Das P., Howard V., Loosbrock N., Dickson D., Murphy M. P. and Golde T. E. (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci. 23, 8532-8538.
32. Das P., Murphy M. P., Younkin L. H., Younkin S. G. and Golde T. E. (2001) Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22, 721-727.
33. De Strooper B., Annaert W., Cupers P. et al. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522.
34. Deane R., Wu Z., Sagare A. et al. (2004b) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
35. Deane R., Wu Z. and Zlokovic B. V. (2004a) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631.
36. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U S A 98, 8850-8855.
37. DeMattos R. B., Bales K. R., Cummins D. J., Paul S. M. and Holtzman D. M. (2002a) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
38. DeMattos R. B., O'Dell M. A., Parsadanian M., Taylor J. W., Harmony J. A., Bales K. R., Paul S. M., Aronow B. J. and Holtzman D. M. (2002b) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U S A 99, 10 843-10 848.
39. Dickey C. A., Dunmore J., Lu B., Wang J. W., Lee W. C., Kamal A., Burrows F., Eckman C., Hutton M. and Petrucelli L. (2006a) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. Faseb J. 20, 753-755.
40. Dickey C. A., Yue M., Lin W. L. et al. (2006b) Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 26, 6985-6996.
41. Dodart J. C., Bales K. R., Gannon K. S. et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457.
42. Dodart J. C., Marr R. A., Koistinaho M., Gregersen B. M., Malkani S., Verma I. M. and Paul S. M. (2005) Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U S A 102, 1211-1216.
43. Dominguez D., Tournoy J., Hartmann D. et al. (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J. Biol. Chem. 280, 30 797-30 806.
44. Donahue C. P., Muratore C., Wu J. Y., Kosik K. S. and Wolfe M. S. (2006) Stabilization of the TAU exon 10 stem loop alters pre-mRNA splicing. J. Biol. Chem. 281, 23 302-23 306.
45. Dodel R. C. Du Y., Depboylu C. et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474.
46. Dyrks T., Weidemann A., Multhaup G., Salbaum J. M., Lemaire H.-G., Kang J., Müller-Hill B., Masters C. L. and Beyreuther K. (1988) Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO J. 7, 949-957.
47. Eckman E. A. and Eckman C. B. (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 1101-1105.
48. Eckman E. A., Reed D. K. and Eckman C. B. (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin- converting enzyme. J. Biol. Chem. 276, 24 540-24 548.
49. Eckman E. A., Watson M., Marlow L., Sambamurti K. and Eckman C. B. (2003) Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278, 2081-2084.
50. Engel T., Hernandez F., Avila J. and Lucas J. J. (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090.
51. Eriksen J. L., Sagi S. A., Smith T. E. et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449.
52. Ertekin-Taner N., Ronald J., Feuk L. et al. (2005) Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum. Mol. Genet. 14, 447-460.
53. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D. and Ward P. J. (1990) Cleavage of amyloid β peptide during constituitive procesing of its precursor. Science 248, 1122-1124.
54. Esler W. P., Kimberly W. T., Ostaszewski B. L., Diehl T. S., Moore C. L., Tsai J. Y., Rahmati T., Xia W., Selkoe D. J. and Wolfe M. S. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol. 2, 428-434.
55. Fagan A. M., Mintun M. A., Mach R. H. et al. (2005) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta (42) in humans. Ann. Neurol. 59, 512-519.
56. Fahrenholz F., Gilbert S., Kojro E., Lammich S. and Postina R. (2000) Alpha-secretase activity of the disintegrin metalloprotease ADAM 10. Influences of domain structure. Ann. N Y Acad. Sci. 920, 215-222.
57. Feyt C., Kienlen-Campard P., Leroy K., N'Kuli F., Courtoy P. J., Brion J. P. and Octave J. N. (2005) Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J. Biol. Chem. 280, 33 220-33 227.
58. Fox N. C., Black R. S., Gilman S., Rossor M. N., Griffith S. G., Jenkins L. and Koller M. (2005) Effects of A{beta} immunization (AN1792) on MRI measures of cerebral Volume in Alzheimer disease. Neurology. 64, 1563-1572.
59. Fox N. C., Crum W. R., Scahill R. I., Stevens J. M., Janssen J. C. and Rossor M. N. (2001) Imaging of onset and progression of Alzheimer's disease with voxel- compression mapping of serial magnetic resonance images. Lancet 358, 201-205.
60. Fraering P. C. Ye W., LaVoie M. J., Ostaszewski B. L., Selkoe D. J. and Wolfe M. S. (2005) gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J. Biol. Chem. 280, 41 987-41 996.
61. Frautschy S. A., Hu W., Kim P., Miller S. A., Chu T., Harris-White M. E. and Cole G. M. (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging 22, 993-1005.
62. Frears E. R., Stephens D. J., Walters C. E., Davies H. and Austen B. M. (1999) The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10, 1699-1705.
63. Frenkel D., Maron R., Burt D. S. and Weiner H. L. (2005) Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115, 2423-2433.
64. Friedhoff P., von Bergen M., Mandelkow E. M. and Mandelkow E. (2000) Structure of tau protein and assembly into paired helical filaments. Biochim. Biophys. Acta 1502, 122-132.
65. Gamblin T. C., Berry R. W. and Binder L. I. (2003) Modeling tau polymerization in vitro: a review and synthesis. Biochemistry 42, 15 009-15 017.
66. Gamblin T. C., King M. E., Dawson H., Vitek M. P., Kuret J., Berry R. W. and Binder L. I. (2000) In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 39, 6136-6144.
67. Gandy S. and Greengard P. (1994) Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. [Review]. Biochimie 76, 300-303.
68. Geschwind D. H. (2003) Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 40, 457-460.
69. Gilman S., Koller M., Black R. S. et al. (2005) Clinical effects of A{beta} immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
70. Glatz D. C., Rujescu D., Tang Y. et al. (2006) The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J. Neurochem. 96, 635-644.
71. Glenner G. G. (1988) Alzheimer's disease: its proteins and genes. Cell 52, 307-308.
72. Goedert M. and Jakes R. (2005) Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739, 240-250.
73. Goedert M., Sisodia S. S. and Price D. L. (1992) Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 8, 159-168.
74. Golde T. E. (2003) Alzheimer disease therapy: Can the amyloid cascade be halted? J. Clin. Invest. 111, 11-18.
75. Golde T. E. (2005) The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 15, 84-87.
76. Golde T. E. and Eckman C. B. (2003) Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. Sci. STKE 2003, RE4.
77. Golde T. E., Eckman C. B. and Younkin S. G. (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502, 172-187.
78. Gotz J., Chen F., Barmettler R. and Nitsch R. M. (2001) Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529-534.
79. Greig N. H., Sambamurti K. YuQ. S., Brossi A., Bruinsma G. B. and Lahiri D. K. (2005) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. 2, 281-290.
80. Guillozet-Bongaarts A. L., Garcia-Sierra F., Reynolds M. R., Horowitz P. M., Fu Y., Wang T., Cahill M. E., Bigio E. H., Berry R. W. and Binder L. I. (2005) Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 26, 1015-1022.
81. Gustke N., Steiner B., Mandelkow E. M., Biernat J., Meyer H. E., Goedert M. and Mandelkow E. (1992) The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett. 307, 199-205.
82. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T. and Hirokawa N. (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491.
83. Hardy J. A. and Higgins G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
84. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
85. Hemming M. L. and Selkoe D. J. (2005) Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 280, 37 644-37 650.
86. Heneka M. T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F. and Landreth G. E. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
87. Hirsch-Reinshagen V., Maia L. F., Burgess B. L. et al. (2005) The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280, 43 243-43 256.
88. Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
89. Holtzman D. M. (2004) In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J. Mol. Neurosci. 23, 247-254.
90. Horowitz P. M., Patterson K. R., Guillozet-Bongaarts A. L., Reynolds M. R., Carroll C. A., Weintraub S. T., Bennett D. A., Cryns V. L., Berry R. W. and Binder L. I. (2004) Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J. Neurosci. 24, 7895-7902.
91. Huang T. H., Yang D. S., Fraser P. E. and Chakrabartty A. (2000a) Alternate aggregation pathways of the Alzheimer beta-amyloid peptide. An in vitro model of preamyloid. J. Biol. Chem. 275, 36 436-36 440.
92. Huang T. H., Yang D. S., Plaskos N. P., Go S., Yip C. M., Fraser P. E. and Chakrabartty A. (2000b) Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297, 73-87.
93. Hussain I., Powell D., Howlett D. R. et al. (1999) Identification of a Novel Aspartic Protease (Asp 2) as beta-Secretase. Mol. Cell Neurosci. 14, 419-427.
94. Hutton M. (2000) Molecular genetics of chromosome 17 tauopathies. Ann. N Y Acad. Sci. 920, 63-73.
95. Hutton M., Lendon C. L., Rizzu P. et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
96. Ikegami S., Harada A. and Hirokawa N. (2000) Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett. 279, 129-132.
97. Irizarry M. C. (2004) Biomarkers of Alzheimer disease in plasma. Neurorx 1, 226-234.
98. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N. P., Gerard C., Hama E., Lee H. J. and Saido T. C. (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550-1552.
99. Iwata N., Tsubuki S., Takaki Y. et al. (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150.
100. Jankowsky J. L., Slunt H. H., Gonzales V. et al. (2005) Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Medical 2, e355.
101. Jarrett J. T. and Lansbury P. T. Jr (1993) Seeding 'one dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and Scrapie? Cell 73, 1055-1058.
102. Kang H. J., Yoon W. J., Moon G. J., Kim D. Y., Sohn S., Kwon H. J. and Gwag B. J. (2005) Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. Neurobiol. Dis 18, 450-458.
103. Khlistunova I., Biernat J., Wang Y., Pickhardt M., von Bergen M., Gazova Z., Mandelkow E. and Mandelkow E. M. (2006) Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205-1214.
104. Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D. P., Bergstrom M., Savitcheva I., Huang G. F., Estrada S., Ausen B., Debnath M. L., Barletta J., Price J. C., Sandell J., Lopresti B. J., Wall A., Koivisto P., Antoni G., Mathis C. A. and Langstrom B. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319.
105. Ko L. W., DeTure M., Sahara N., Chihab R. and Yen S. H. (2002) Cellular models for tau filament assembly. J. Mol. Neurosci. 19, 311-316.
106. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K. R. and Paul S. M. (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10, 719-726.
107. Kojro E. and Fahrenholz F. (2005) The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem. 38, 105-127.
108. Kojro E., Gimpl G., Lammich S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl Acad. Sci. U S A 98, 5815-5820.
109. Koldamova R., Staufenbiel M. and Lefterov I. (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280, 43 224-43 235.
110. Koo E. H. (1997) Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production. Mol. Med. 3, 204-211.
111. Koo E. H., Lansbury P. T. Jr and Kelly J. W. (1999) Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl Acad. Sci. U S A 96, 9989-9990.
112. Kukar T., Murphy M. P., Eriksen J. L., Sagi S. A., Weggen S., Smith T. E., Ladd T., Khan M. A., Kache R., Beard J., Dodson M., Merit S., Ozols V. V., Anastasiadis P. Z., Das P., Fauq A., Koo E. H. and Golde T. E. (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 11, 545-550.
113. Laird F. M., Cai H., Savonenko A. V., Farah M. H., He K., Melnikova T., Wen H., Chiang H. C., Xu G., Koliatsos V. E., Borchelt D. R., Price D. L., Lee H. K. and Wong P. C. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11 693-11 709.
114. Lam F. C., Liu R., Lu P., Shapiro A. B., Renoir J. M., Sharom F. J. and Reiner P. B. (2001) beta-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 1121-1128.
115. Lazarov O., Robinson J., Tang Y. P., Hairston I. S., Korade-Mirnics Z., Lee V. M., Hersh L. B., Sapolsky R. M., Mirnics K. and Sisodia S. S. (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701-713.
116. Le G. T. and Abbenante G. (2005) Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. Curr. Med. Chem. 12, 2963-2977.
117. Le Corre S., Klafki H. W., Plesnila N. et al. (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl Acad. Sci. U S A 103, 9673-9678.
118. Ledesma M. D., Da Silva J. S., Crassaerts K., Delacourte A., De Strooper B. and Dotti C. G. (2000) Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 1, 530-535.
119. Lee V. M., Goedert M. and Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
120. Lee V. M.-Y. and Trojanowski J. Q. (1992) The disordered neuronal cytoskeleton in Alzheimer's disease. Current Opinion Neurobiol. 2, 653-656.
121. Leenders K. L. and Oertel W. H. (2001) Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions. Neural. Plast. 8, 99-110.
122. Leissring M. A., Farris W., Chang A. Y., Walsh D. M., Wu X., Sun X., Frosch M. P. and Selkoe D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
123. Levites Y., Amit T., Mandel S. and Youdim M. B. (2003) Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. Faseb J. 17, 952-954.
124. Levites Y., Smithson L. A., Price R. W. et al. (2006) Insights into the Mechanisms of Action of Anti-Aβ Antibodies in Alzheimer's Disease Mouse Models. FASEB J. in press
125. Lewis J., Dickson D. W., Lin W. L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
126. Lewis J., McGowan E., Rockwood J. et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405.
127. Li Y. M., Xu M., Lai M. T. et al. (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694.
128. Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A. and Cole G. M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377.
129. Lipton S. A. (2005) The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2, 155-165.
130. Lleo A., Berezovska O., Herl L., Raju S., Deng A., Bacskai B. J., Frosch M. P., Irizarry M. and Hyman B. T. (2004) Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 10, 1065-1066.
131. Lu P. J., Wulf G., Zhou X. Z., Davies P. and Lu K. P. (1999) The prolyl isomerase PIN1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399, 784-788.
132. Luo Y., Bolon B., Kahn S. et al. (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231-232.
133. Maier M., Seabrook T. J., Lazo N. D., Jiang L., Das P., Janus C. and Lemere C. A. (2006) Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26, 4717-4728.
134. Maier M., Seabrook T. J. and Lemere C. A. (2005) Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G). Vaccine 23, 5149-5159.
135. Marr R. A., Rockenstein E., Mukherjee A., Kindy M. S., Hersh L. B., Gage F. H., Verma I. M. and Masliah E. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992-1996.
136. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. and Schenk D. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131.
137. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings Natl. Acad. Sci. USA 82, 4245-4249.
138. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., Hisanaga S., Goedert M. and Hasegawa M. (2006) Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45, 6085-6094.
139. Matsubara E., Frangione B. and Ghiso J. (1995) Characterization of apolipoprotein J-Alzheimer's A beta interaction. J. Biol. Chem. 270, 7563-7567.
140. Matsuoka Y., Saito M., LaFrancois J. et al. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23, 29-33.
141. McGeer P. L., Schulzer M. and McGeer E. G. (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies [see comments]. Neurology 47, 425-432.
142. McLaurin J., Franklin T., Zhang X., Deng J. and Fraser P. E. (1999) Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem. 266, 1101-1110.
143. McLaurin J., Golomb R., Jurewicz A., Antel J. P. and Fraser P. E. (2000) Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J. Biol. Chem. 275, 18 495-18 502.
144. McLaurin J., Kierstead M. E., Brown M. E. et al. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808.
145. Mohajeri M. H., Kuehnle K., Li H., Poirier R., Tracy J. and Nitsch R. M. (2004) Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. FEBS Lett. 562, 16-21.
146. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T. and Weiner H. L. (2006) Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U S A 103, 5048-5053.
147. Nacharaju P., Lewis J., Easson C., Yen S., Hackett J., Hutton M. and Yen S. H. (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett. 447, 195-199.
148. Nakashima H., Ishihara T., Suguimoto P. et al. (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol (Berl) 110, 547-556.
149. Narindrasorasak S., Lowery D., Gonzalez-DeWhitt P., Poorman R. A., Greenberg B. and Kisilevsky R. (1991) High affinity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J. Biol. Chem. 266, 12 878-12 883.
150. Netzer W. J., Dou F., Cai D., Veach D., Jean S., Li Y., Bornmann W. G., Clarkson B., Xu H. and Greengard P. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl Acad. Sci. U S A 100, 12 444-12 449.
151. Newman J., Rissman R. A., Sarsoza F., Kim R. C., Dick M., Bennett D. A., Cotman C. W., Rohn T. T. and Head E. (2005) Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol (Berl) 110, 135-144.
152. Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452.
153. Nilsson L. N., Bales K. R., DiCarlo G., Gordon M. N., Morgan D., Paul S. M. and Potter H. (2001) Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 1444-1451.
154. Nitsch R. M. (1996) From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 5, 477-482.
155. Noble W., Olm V., Takata K. et al. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
156. Noble W., Planel E., Zehr C. et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. U S A 102, 6990-6995.
157. Obregon D. F., Rezai-Zadeh K., Bai Y. et al. (2006) ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 281, 16 419-16 427.
158. Oda T., Wals P., Osterburg H. H. et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136, 22-31.
159. Orgogozo J. M., Gilman S., Dartigues J. F. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
160. Pastorino L., Sun A., Lu P. J. et al. (2006) The prolyl isomerase PIN1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440, 528-534.
161. Pedrini S., Carter T. L., Prendergast G., Petanceska S., Ehrlich M. E. and Gandy S. (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Medical 2, e18.
162. Permanne B., Adessi C., Saborio G. P. et al. (2002) Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. Faseb J. 16, 860-862.
163. Petrucelli L., Dickson D., Kehoe K. et al. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703-714.
164. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P. M. and Jucker M. (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298, 1379.
165. Phiel C. J., Wilson C. A., Lee V. M. and Klein P. S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439.
166. Plattner F., Angelo M. and Giese K. P. (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281, 25 457-25 465.
167. Postina R., Schroeder A., Dewachter I. et al. (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 1456-1464.
168. Potter H., Wefes I. M. and Nilsson L. N. (2001) The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol. Aging 22, 923-930.
169. Price D. L. and Sisodia S. S. (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neuroscience 21, 479-505.
170. Price D. L., Tanzi R. E., Borchelt D. R. and Sisodia S. S. (1998) Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32, 461-493.
171. Qiu W. Q., Walsh D. M. Ye Z. et al. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta- protein by degradation. J. Biol. Chem. 273, 32 730-32 738.
172. Racke M. M., Boone L. I., Hepburn D. L. et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25, 629-636.
173. Refolo L. M. and Fillit H. M. (2004) Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease. J. Mol. Neurosci. 23, 151-155.
174. Refolo L. M., Pappolla M. A., LaFrancois J. et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890-899.
175. Rezai-Zadeh K., Shytle D., Sun N. et al. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814.
176. Ringman J. M., Frautschy S. A., Cole G. M., Masterman D. L. and Cummings J. L. (2005) A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. 2, 131-136.
177. Rissman R. A., Poon W. W., Blurton-Jones M., Oddo S., Torp R., Vitek M. P., LaFerla F. M., Rohn T. T. and Cotman C. W. (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121-130.
178. Rockenstein E., Adame A., Mante M., Moessler H., Windisch M. and Masliah E. (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J. Neural. Transm. 110, 1313-1327.
179. Rosenberg R. N. (2005) Translational research on the way to effective therapy for Alzheimer disease. Arch. General Psychiatry 62, 1186-1192.
180. Rossner S., Beck M., Stahl T., Mendla K., Schliebs R. and Bigl V. (2000) Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation. Eur. J. Neurosci. 12, 3191-3200.
181. Sadowski M., Pankiewicz J., Scholtzova H. et al. (2004) A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 165, 937-948.
182. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S. M., Suemoto T., Higuchi M. and Saido T. C. (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 11, 434-439.
183. Santacruz K., Lewis J., Spires T. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
184. Sastre M., Dewachter I., Landreth G. E., Willson T. M., Klockgether T., van Leuven F. and Heneka M. T. (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23, 9796-9804.
185. Saxena M. T., Schroeter E. H., Mumm J. S. and Kopan R. (2001) Murine notch homologs (n1-4) undergo presenilin-dependent proteolysis. J. Biol. Chem. 276, 40 268-40 273.
186. Schenk D. (2002) Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev. Neurosci. 3, 824-828.
187. Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
188. Seabrook T. J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G. and Lemere C. A. (2006) Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging.
189. Seiffert D., Bradley J. D., Rominger C. M. et al. (2000) Presenilin-1 and - 2 are molecular targets for gamma-secretase inhibitors [In Process Citation]. J. Biol. Chem 275, 34 086-34 091.
190. Selkoe D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
191. Selkoe D. and Kopan R. (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565-597.
192. Shimura H., Schwartz D., Gygi S. P. and Kosik K. S. (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. 279, 4869-4876.
193. Shirotani K., Tsubuki S., Iwata N. et al. (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem. 276, 21 895-21 901.
194. Siemers E., Skinner M., Dean R. A., Gonzales C., Satterwhite J., Farlow M., Ness D. and May P. C. (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126-132.
195. Sigurdsson E. M., Permanne B., Soto C., Wisniewski T. and Frangione B. (2000) In vivo reversal of amyloid-beta lesions in rat brain. J. Neuropathol. Exp. Neurol. 59, 11-17.
196. Singer O., Marr R. A., Rockenstein E., Crews L., Coufal N. G., Gage F. H., Verma I. M. and Masliah E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 1343-1349.
197. Sinha S., Anderson J. P., Barbour R. et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain [In Process Citation]. Nature 402, 537-540.
198. Sisodia S. S., Koo E. H., Beyreuther K., Unterbeck A. and Price D. L. (1990) Evidence that β-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248, 492-495.
199. Skovronsky D. M., Moore D. B., Milla M. E., Doms R. W. and Lee V. M. (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 275, 2568-2575.
200. van Slegtenhorst M., Lewis J. and Hutton M. (2000) The molecular genetics of the tauopathies. Exp. Gerontol. 35, 461-471.
201. Small G. W., Mazziotta J. C., Collins M. T. et al. (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. Jama 273, 942-947.
202. Small D. H., Mok S. S. and Bornstein J. C. (2001) Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2, 595-598.
203. Snow A. D., Sekiguchi R., Nochlin D., Fraser P., Kimata K., Mizutani A., Arai M., Schreier W. A. and Morgan D. G. (1994) An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 12, 219-234.
204. Soto C. and Estrada L. (2005) Amyloid inhibitors and beta-sheet breakers. Subcell Biochem. 38, 351-364.
205. Sparks D. L., Sabbagh M. N., Connor D. J. et al. (2005) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res. 2, 343-353.
206. Spillantini M. G., Murrell J. R., Goedert M., Farlow M. R., Klug A. and Ghetti B. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. U S A 95, 7737-7741.
207. Stewart W. F., Kawas C., Corrada M. and Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use [see comments]. Neurology 48, 626-632.
208. Strittmatter W. J. and Roses A. D. (1995) Apolipoprotein E and Alzheimer disease. Proc. Natl Acad. Sci. U S A 92, 4725-4727.
209. Takaki Y., Iwata N., Tsubuki S. et al. (2000) Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J. Biochem. (Tokyo) 128, 897-902.
210. Takei Y., Teng J., Harada A. and Hirokawa N. (2000) Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J. Cell Biol. 150, 989-1000.
211. Tariot P. N., Farlow M. R., Grossberg G. T., Graham S. M., McDonald S. and Gergel I. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 291, 317-324.
212. Thal L. J., Kantarci K., Reiman E. M. et al. (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, 6-15.
213. Thomas L. (2005) Pgp deficiency increases amyloid concetrations in the brain. Lancet Neurol. 4, 798-799.
214. Tucker H. M., Kihiko M., Caldwell J. N. et al. (2000b) The plasmin system is induced by and degrades amyloid-beta aggregates. J. Neurosci. 20, 3937-3946.
215. Tucker H. M., Kihiko-Ehmann M., Wright S., Rydel R. E. and Estus S. (2000a) Tissue plasminogen activator requires plasminogen to modulate amyloid- beta neurotoxicity and deposition. J. Neurochem. 75, 2172-2177.
216. Tucker H. M., Simpson J., Kihiko-Ehmann M., Younkin L. H., McGillis J. P., Younkin S. G., Degen J. L. and Estus S. (2004) Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. Neurosci. Lett. 368, 285-289.
217. Tuszynski M. H., Thal L., Pay M. et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551-555.
218. Utsuki T., Yu Q. S., Davidson D., Chen D., Holloway H., Brossi A., Sambamurti K., Lahiri D., Greig N. H. and Giordano T. (2006) Identification of Novel Small Molecule Inhibitors of APP Protein Synthesis as a Route to Lower Alzheimer's disease Amyloid-{beta} peptide. J. Pharmacol. Exp. Ther. 318, 855-862.
219. Vardy E. R., Catto A. J. and Hooper N. M. (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 11, 464-472.
220. Vassar R., Bennett B., Babu-Khan S., Rogers G. and Citron M. (1999) Beta-Secretase celavage of Alzheimer's Amyloid Precursor Protein by the transmembrane aspartic protease BACE. Science 286, 735-740.
221. in 't Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M. and Stricker B. H. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521.
222. in 't Veld B. A., Launer L. J., Hoes A. W., Ott A., Hofman A., Breteler M. M. and Stricker B. H. (1998) NSAIDs and incident Alzheimer's disease. The Rotterdam Study [see comments]. Neurobiol. Aging 19, 607-611.
223. Wahrle S. E., Jiang H., Parsadanian M., Hartman R. E., Bales K. R., Paul S. M. and Holtzman D. M. (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43 236-43 242.
224. Walsh D. M. and Selkoe D. J. (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193.
225. Watson G. S., Peskind E. R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M. W., Plymate S. and Craft S. (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903.
226. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
227. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Ozols V., Fauq A., Golde T. E. and Koo E. H. (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 278, 31 831-31 837.
228. Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J. M., Masters C. L. and Beyreuther K. (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57, 115-126.
229. Weiner H. L. and Frenkel D. (2006) Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6, 404-416.
230. Wilcock D. M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K. E., Gordon M. N. and Morgan D. (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 3745-3751.
231. Wilcock D. M., Gordon M. N., Ugen K. E. et al. (2001) Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 20, 731-736.
232. Wilcock D. M., Rojiani A., Rosenthal A., Subbarao S., Freeman M. J., Gordon M. N. and Morgan D. (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1, 24.
233. Wischik C. M., Edwards P. C., Lai R. Y., Roth M. and Harrington C. R. (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. U S A 93, 11 213-11 218.
234. Wisniewski T. and Frangione B. (2005) Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 15, 72-77.
235. Wolozin B. (2001) A fluid connection: cholesterol and Abeta. Proc. Natl Acad. Sci. U S A 98, 5371-5373.
236. Yan R., Bienkowski M. J., Shuck M. E. et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta- secretase activity. Nature 402, 533-537.
237. Yan R., Munzner J. B., Shuck M. E. and Bienkowski M. J. (2001) BACE2 functions as an alternative alpha-secretase in cells. J. Biol. Chem. 276, 34 019-34 027.
238. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A. L., Citron M. and Landreth G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509.
239. Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901.
240. Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L. and Neve R. L. (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420.
241. Younkin S. G. (1998) The role of A beta 42 in Alzheimer's disease. J. Physiol., Paris 92, 289-292.
242. Zandi P. P., Carlson M. C., Plassman B. L., Welsh-Bohmer K. A., Mayer L. S., Steffens D. C. and Breitner J. C. (2002) Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. Jama 288, 2123-2129.
243. Zhang B., Maiti A., Shively S. et al. (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. U S A 102, 227-231.
244. Zhou X. Z., Kops O., Werner A. et al. (2000) PIN1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 6, 873-883.
245. Zlokovic B. V. (2004) Clearing amyloid through the blood-brain barrier. J. Neurochem. 89, 807-811.
246. Zlokovic B. V., Deane R., Sallstrom J., Chow N. and Miano J. M. (2005) Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol. 15, 78-83.
247. Zurbriggen R., Amacker M., Kammer A. R., Westerfeld N., Borghgraef P., Van Leuven F., Van der Auwera I. and Wera S. (2005) Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 27, 157-166.